A Shared-Value Model for Enhancing Diabetes Care in South Africa

By Rene Pretorius

April 4, 2025

diabetes care South Africa

Summary

In a world where diabetes management demands both innovation and integration, DiaCision is at the forefront, using AI-driven insights to improve outcomes and reshape the way care is delivered. As we look for transformative models that go beyond traditional approaches, the article “Improving Diabetes Care in South Africa Through a Shared-Value Model” offers an important case study.

This piece reviews a program by Discovery Health, launched in 2021, that aims to enhance diabetes care in South Africa through a shared-value approach. By focusing on improving hemoglobin A1c testing rates, glycemic control, and disease stability, the program has demonstrated measurable success over three years. Notably, it has also contributed to reduced hospital admissions and healthcare costs. In the broader context of advancing diabetes care, this model presents a compelling example of how aligning patient outcomes with system-wide value can lead to scalable, sustainable impact.

Key Insights

  • Shared-Value Model: The program incentivizes medical practitioners to improve diabetes care, leading to better patient outcomes.
  • Glycemic Control and Stability: HbA1c testing rates, glycemic control, and disease stability improved notably.
  • Economic Benefits: Hospital admissions and healthcare costs decreased, suggesting long-term savings.

Background Context

Diabetes is a major global health challenge. The WHO highlights its rising prevalence and the need for effective management. In South Africa, healthcare access varies. Shared-value programs can help bridge gaps in diabetes care in South Africa. The WHO stresses cost-effective interventions that prioritize patient outcomes, aligning with shared-value models.

Implications

This shared-value model has significant implications:

  • Healthcare Cost Reduction: Better diabetes management reduces admissions and costs.
  • Improved Patient Outcomes: Enhanced glycemic control and stability reduce complications and improve quality of life.
  • Scalability and Adaptability: Such programs can inspire similar initiatives elsewhere, aiding broader healthcare reform.

The content highlights innovative healthcare models’ role in improving patient outcomes. Insights from value-based care discussions suggest these models are key to better health outcomes and cost control. For more details, see the original article here.

Reference url

Recent Posts

Joint Scientific Consultation EU
Joint Scientific Consultation EU Strategies for Medical Device Companies

By João L. Carapinha

June 19, 2026

The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their developme...
USTR Germany Pharma Investigation
USTR Germany Pharma Investigation and its Impact on Global Drug Pricing

By João L. Carapinha

June 19, 2026

The USTR Germany Pharma Investigation has exposed how Germany’s pharmaceutical reimbursement policies force American patients to finance a disproportionately large share of worldwide drug research and development. By systematically suppressing prices below sustainable levels, these practices erod...
real-world evidence Portugal
Enhancing Health Technology Assessment Through Real-World Evidence in Portugal

By João L. Carapinha

June 17, 2026

Real-world evidence Portugal has moved from supplementary tool to statutory requirement under Decree-Law 118/2026, which compels national health systems to share interoperable data so that promised outcomes can be verified after medicines and devices reach patients. The legislation converts one-t...